Sponsorship Alliance News

News from Our Sponsorship Alliance Partners

March 2023


RefleXion Announces Installation of X1 Platform at Smilow Cancer Hospital at Yale New Haven

We are excited to announce the installation of the RefleXion® X1 platform at Smilow Cancer Hospital, part of Yale New Haven Health, Connecticut’s largest healthcare system. “Our hope is that SCINTIX therapy will allow us to expand the reach of radiotherapy as an option for patients with metastatic cancer and combine it with other treatments to improve outcomes for our patients,” said Peter Glazer, M.D, Ph.D., chair of the Department of Therapeutic Radiology at Yale School of Medicine and chief of Radiation Oncology at Smilow Cancer Hospital at Yale New Haven.

February 2023


Accuray Press Release: European Radiosurgery Center Munich Invests in Second Accuray CyberKnife® System to Support the Demand for High-Precision Radiosurgery Treatments

On January 26, 2023, Accuray Incorporated announced that the European Radiosurgery Center Munich has selected a second CyberKnife® System, the latest generation CyberKnife S7™ System, to enable their team to treat the high volume of patients they see in their practice who would benefit from the extremely precise radiation treatments it delivers. The Center was an early adopter of CyberKnife radiosurgery and continues to pioneer new ways to use the system in the non-invasive treatment of certain neurological conditions and tumors. ~The center believes the CyberKnife System is the #1 tool for delivery of advanced radiosurgery treatments.


RefleXion Receives FDA Clearance for SCINTIX Biology-Guided Radiotherapy; Cutting-edge Treatment Applicable for Early and Late-stage Cancers

SCINTIX™ biology-guided radiotherapy is now cleared by the FDA to treat patients with lung and bone tumors. SCINTIX therapy is the first and only radiotherapy that allows each cancer’s unique biology to autonomously determine where and how much radiation to deliver, second-by-second, during actual treatment delivery. This expands the RefleXion® X1 into the only dual-treatment modality platform that can treat patients with indicated solid tumors of any stage.


University Hospitals in Cleveland Enters into Master Purchase Agreement with ViewRay for Multiple MRIdian Systems

University Hospitals (UH) Seidman Cancer Center in Cleveland has selected a MRIdian MR-Guided Radiation Therapy System as part of a master agreement for the purchase of up to four systems, and will be the first in Ohio at a research and teaching hospital to offer the precision of MRIdian's advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, kidney, gynecological, lung, liver, breast, brain, spine, and oligometastatic cancers.

Chindex Medical Acquires 10 ViewRay MRIdian Systems for Advanced Cancer Treatment

Chindex Medical Limited (Chindex), through its subsidiary, has ordered 10 MRIdian® MR-Guided Therapy Systems. This approval expands MRIdian's global reach and offers cancer patients a new radiation therapy option, MRIdian Stereotactic MRI-Guided Adaptive Radiotherapy (SMART).

Findings Published in JAMA Oncology Demonstrate Superiority of MRIdian MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

Findings from the phase III randomized controlled MIRAGE trial (NCT04384770) were published on January 12 in JAMA Oncology. The MIRAGE trial compared MRI-guided and CT-guided stereotactic body radiation therapy (SBRT) for localized prostate cancer and found MRI-guided radiation therapy – delivered with MRIdian – to be superior in substantially reducing acute genitourinary (GU) and gastrointestinal (GI) toxicity. MRI-guided radiation was also associated with significantly better patient-reported quality of life metrics.

JunXin Oncology

Junxin Oncology Group and BOAO Evergrande International Hospital (BEIH) signed a Strategic Partnership Agreement – Enhancing the Radiation Oncology Services in Hainan Province

On January 1, 2023, Junxin Oncology Group and BOAO Evergrande International Hospital formed a partnership for cancer care, and Junxin will provide daily management and operation of the radiation oncology department at BOAO. The hospital is located at Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China. This hospital had been affiliated to Brigham and Women’s Hospital (BWH) for five years from 2016 to 2021. With this addition, Junxin is providing cancer care for more than 2000 patients annually at its four cancer centers distributed throughout four provinces in China as a medical group founded just three years ago. All of Junxin’s resources, such as MDT, chart round, internal training, cloud-based management, medical experts, will be available for BOAO.

January 2023


Accuray Exchange

The Accuray Exchange (AEx) is the peer-to-peer community of Accuray technology users with a wide range of resources available to support daily practice. Make joining the AEx one of your New Year resolutions for 2023! Join Now.


"Stay in the Game: Conversations About Prostate Cancer" podcast features Dr. Himanshu Nagar and MRIdian MR-guided radiation therapy

Assistant Professor of Radiation Oncology at Weill Cornell Medicine in New York City, Dr. Himanshu Nagar supervises the region’s only MRIdian MR-guided radiation therapy machine, created by ViewRay. MRIdian provides MRI-guided radiotherapy, which leads to a more precise prostate cancer treatment while significantly limiting or eliminating the side effects of treatment.

The initial experience of MRI-guided precision prone breast irradiation with daily adaptive planning in treating early stage breast cancer patients

A paper authored by John Ng, MD, Ryan Pennell, MBA, and Sylvia Formenti, MD has been published to study the feasibility of delivering MRI-guided partial breast radiotherapy or Precision Prone Irradiation (PPI) to treat DCIS and early stage breast cancer patients. The study concludes that MRI-guided partial breast radiotherapy as a breast radiotherapy technology is feasible and is a potential high clinical impact application of MRgRT. PPI has the potential to improve the therapeutic index of breast radiotherapy by more accurately delivering radiation dose to the cavity target and decreasing toxicities associated with radiation to the surrounding normal tissues.

ZAP Surgical

ZAP Surgical releases a brand-new planning study! Large Meningioma – Protecting the Optic Apparatus

The target: a substantial 9.42 cc tumor. The treatment: world-class ZAP-X SRS with a remarkably low 5.9 Gy max dose to the optic chiasm. To understand how the vault-free, cobalt-free ZAP-X defines new standards in SRS dosimetry, request the study at info@zapsurgical.com

VIVE LA FRANCE! Parisian Hospital Expands Program with Dedicated SRS

The first ZAP-X installation in France is complete! Congratulations to the Centre de Cancérologie de la Porte de Saint-Cloud (CCPSC) in Boulogne-Billancourt. First patient treatments expected to begin early 2023. Constrained by a small space in a crowded urban setting, see the vault-free ZAP-X find its new home in a retrofitted conventional radiation bunker. Watch the video at https://www.youtube.com/watch?v=hKY7DSKeMDo

ZAP Surgical Announces Rapid Global Expansion with the First ZAP-X Gyroscopic Radiosurgery Platform Installation in Poland

University Hospital in Olsztyn to become the first in Poland to offer vault-free, cobalt-free ZAP-X Gyroscopic Radiosurgery - the latest advance in surgical robotics. First patient treatments expected to commence in early 2023.

December 2022

Vision RT, Inc.

Abstracts Open: US Annual SGRT Community Meeting

As the sponsor of the meeting, Vision RT announces that abstracts are open for the US Annual SGRT Community Meeting, being held in the fabulous, retro-futuristic TWA hotel in New York's JFK airport on May 11 - 12, 2023. We invite you to submit on any surface guidance topic. Travel grants are available for successful submissions. The abstract window will close on Monday, February 6, 2023.

Attendance to this event will be completely FREE and 100% peer-driven, with all sessions and talks delivered by SGRT users. As in previous years, the two-day event will be made up of presentations, workshops, latest innovations and applications, real-life case reports, and fun networking with peers and vendors.

November 2022

Vision RT, Inc.

2,000 SGRT Systems in Clinical Use Worldwide

Founded in 2001, Vision RT invented SGRT and remains the market leader in this field. SGRT makes every step of radiotherapy safer, more effective, and more comfortable for patients. Today, we celebrate an important milestone:  more than 2,000 systems in active clinical use, worldwide.

Vision RT’s technology is used by all 15 of the top “Best Hospitals for Cancer” in the US and in 39 of the top 50. We have partnered with clinics to transform SGRT from a niche technology to a core part of a new standard of care, with AAPM guidelines on its use and applications for more than 10 different cancer types.


Check out the updated Accuray Exchange

Accuray Exchange (AEx), the peer community for Accuray users has been transformed. The site has a new look but that's not all, there is a new discussion forum to support members in their daily practice. Join today and start availing of the benefits. Connect. Exchange. Learn.


RefleXion Unveils SCINTIX™ Technology for Patients with Any Stage of Cancer

RefleXion's newly named SCINTIX biology-guided radiotherapy combines radiotherapy with PET-CT to treat cancer using PET emissions created by the tumor itself. SCINTIX technology leverages radiotracers to track both expected and unexpected tumor motion. Click the button below to learn more.

RefleXion Highlights New Cancer Treatment Research Abstracts for Presentation at ASTRO 2022

Researchers presented eight abstracts evaluating the potential use of SCINTIX™ biology-guided radiotherapy. Two abstracts were also showcased during ASTRO's Quick Pitch session on "PET and Novel Techniques for Treatment."


Elekta Esprit receives U.S. FDA 510(k) clearance

Elekta Esprit, the new Leksell Gamma Knife® radiosurgery platform, recently showcased at ASTRO, received U.S. FDA 510(k) clearance on 28th October 2022.

Esprit combines a variety of innovations in a single platform. Leksell Gamma Knife® Lightning allows for high quality plan creation in <1 min further enabling same day radiosurgery. Esprit offers clinicians the option of frameless or frame-based workflows with the new Vantage™ system. Esprit targets the smallest and most challenging intracranial tumors and lesions with minimal effect on healthy tissue. This vital precision makes Esprit the gold standard in radiosurgery. Elekta Esprit - Protect the mind, protect the person.


San Pietro Fatebenefratelli Hospital Treats its 1,000th Patient with MRIdian MRI-Guided Radiation Therapy

The center reached the patient milestone in less than three years by leveraging MRIdian to treat a wide variety of patients including those with complex and hard to treat tumors, demonstrating the system's efficiency and clinical value.

SUNY Upstate Cancer Center Chooses ViewRay's MRI-Guided Radiation Therapy System to Treat Cancer Patients

ViewRay announced that SUNY Upstate Cancer Center in Syracuse, New York has selected MRIdian MRI-Guided Radiation Therapy System and will be the first in Upstate New York to offer the precision of MRIdian's advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, lung, liver, breast, and oligometastatic cancers.

ViewRay Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

LAP-ABLATE, a prospective multi-center international randomized controlled trial will compare 2-year overall survival in pancreatic cancer patients receiving post-chemotherapy ablative MRIdian SMART vs. chemotherapy alone.

ViewRay Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

The primary objective of the SMART Pancreas study of low grade 3+ toxicity was met; exploration of secondary outcomes underway to confirm local control rates and patient outcomes with MRIdian SMART.

MIRAGE Phase III Randomized Controlled Trial Demonstrates Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

Final outcomes comparing acute grade ≥2 genitourinary toxicity following MRI- vs. CT-guided prostate SBRT presented at ASTRO 2022.

ZAP Surgical

The First Installation of the Vault-Free, Cobalt-Free ZAP-X in Central Europe has Commenced

Medical University of Olsztyn in Poland to soon offer the latest advance in dedicated cranial radiosurgery.

ZAP-X: Boldly Going Where No SRS System Has Gone Before

Ever wonder what a vault-free ZAP-X might look like in a hospital lobby, a meeting space, or an empty room? Well now you can! Using a mobile phone or tablet, see the ZAP-X anywhere, anytime in 360-degrees. Just click below and follow the prompts (use a mobile phone or tablet).

October 2022


RefleXion recognized by Built In as a company that delivers solutions in healthcare through technological innovation

Built In recognizes RefleXion as an organization delivering on the search for solutions to new and longstanding problems in healthcare. Gopi Kuduvalli, Ph.D., vice president of product engineering, talked with Built In about RefleXion's work to create a new cancer treatment modality through biological guidance.


ViewRay Announces China NMPA Approval of its MRIdian® MRI-Guided Radiation Therapy for Cancer Patients

DENVER, Sept. 7, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company's MRIdian MRI-Guided Radiation Therapy System has received approval from the Chinese regulatory authority National Medical Products Administration (NMPA), allowing for its sale and utilization throughout China.

GenesisCare Purchases Two Additional ViewRay MRIdian MRI-guided Radiotherapy Systems for Guildford and Birmingham Projects, Doubling United Kingdom Footprint to Four Systems

New agreement expands access to precision radiotherapy to more cancer patients in the UK.

MD Anderson Cancer Center Selects ViewRay to Expand MR-Guided Radiation Therapy Program

First MRIdian system to be installed at MD Anderson main campus at the Texas Medical Center in Houston.

ZAP Surgical

ZAP-X: Boldly Going Where No SRS System Has Gone Before

Ever wonder what a vault-free ZAP-X might look like in a hospital lobby, a meeting space, or an empty room? Well now you can! Using a mobile phone or tablet, see the ZAP-X anywhere, anytime in 360-degrees. Just click below and follow the prompts. (Reminder: use a mobile phone or tablet).

The Institut du Cancer Courlancy in Reims, France to Acquire the Advanced ZAP-X Gyroscopic Radiosurgery Platform

Site to be Among Europe’s First to Offer Groundbreaking Innovation in Non-Invasive Treatment for Brain Tumors.